2023 Top 10 Pharma & Biopharma Preview

The following is a preview of Contract Pharma’s upcoming Top 20 Companies Report based on 2022 Pharmaceutical Rx sales in $U.S. millions. 
(excludes consumer healthcare, medical device, diagnostics division sales)
 
Our annual look at the 20 biggest Pharma and Biopharma players highlights key financials, top selling drugs, acquisitions & alliances, drug approvals, pipeline advances, significant personnel moves, and more. 

1. Pfizer: $100,330 
2. Merck: $59,283 
3. Abbvie: $58,054
4. Roche: $52,650 
5. Johnson & Johnson: $52,563 
6. Novartis $50,545 
7. Bristol Myers Squibb: $46,159 
8. Sanofi $45,899 
9. AstraZeneca: $44,351 
10. GlaxoSmithKline: $35,360 
 
Pfizer
Headcount:~83,000
Revenues: $100,330 (+23%)
Net Income: $31,372 (+43%)
R&D expenses: $11,428 (+10%)
 
Merck
Headcount: 69,000 
Revenues: $59,283 (+22%)
Net Income: $14,519 (+18%) 
R&D expenses: $13,548 (+11%)
 
Abbvie
Headcount: ~50,000
Revenues: $58,054 (+14%)
Net Income: $11,845 (+3%) 
R&D expenses: $6,510 (-6%)
 
Roche 
Headcount: 104,000
Revenues: $71,920 (+1%)
Pharma Revenues: $52,650 (+1%)
Net Income: $14,650 (-9%)
R&D: $17,348 (+8%)
 
Johnson & Johnson
Headcount: 153,000
Revenues: $94,943 (+1%)
Pharma Revenues: $52,563 (+2%)
Net Income: $17,941 (-14%) 
R&D expenses: $14,603 (-1%)
 
Novartis
Headcount: 101,703
Revenues: $50,545 (-2%)
Net Income: $6,955 (-71%) 
R&D expenses: $9,996 (+5%)
 
Bristol Myers Squibb
Headcount: 34,300
Revenues: $46,159 (+3%)
Net Income: $6,345 (-10%)
R&D expenses: $9,509 (-7%)
 
Sanofi
Headcount: 91,573
Revenues: $45,899 (+14%)
Net Income: $7,174 (+8%) 
R&D expenses: $7,159 (+18%) 
 
AstraZeneca
Headcount: 83,500
Revenues: $44,351 (+19%)
Net Income: $3,293 (n/m) 
R&D expenses: $9,762 (flat)
 
GlaxoSmithKline
Headcount: 69,400 
Revenues: $35,360 (+4%)
Net Income: $18,836 (>100%) 
R&D expenses: $6,618 (+9%)

Coming soon, Contract Pharma’s July/August Top 20 Companies Report!